SCHEMBL4254017

SCHEMBL4254017

COC(=O)c1ccc2c(c1)[nH]c(=O)n2C

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 9/20 0.54
ALDH1A1 P00352 8/20 0.54
GAA P10253 7/20 0.54
HPGD P15428 4/20 0.54
HSD17B10 Q99714 4/20 0.54
GLA P06280 3/20 0.54
KMT2A Q03164 3/20 0.54
PKM P14618 2/20 0.54
HTT P42858 2/20 0.54
PARP1 P09874 2/20 0.49
KIF11 P52732 1/20 0.49
CREBBP Q92793 1/20 0.48
CASP3 P42574 1/20 0.48
LMNA P02545 1/20 0.47
MEN1 O00255 2/20 0.46
FGFR1 P11362 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
TP53 P04637 1/20 0.45
POLB P06746 1/20 0.45
MAPT P10636 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31473393 0.90 ALDH1A1 (0.48) KDM4EALDH1A1GAAHPGDHSD17B10
SCHEMBL1759187 0.88 CREBBP (0.51) KDM4EALDH1A1GAAHPGDHSD17B10
SCHEMBL27541312 0.84 ALDH1A1 (0.61) KDM4EALDH1A1GAAHPGDHSD17B10
SCHEMBL29670373 0.83 ALDH1A1 (0.52) KDM4EALDH1A1GAAHPGDHSD17B10
SCHEMBL21156821 0.83 LMNA (0.51) KMT2ALMNAMEN1FGFR1TP53
SCHEMBL1759317 0.83 ALDH1A1 (0.52) KDM4EALDH1A1GAAHPGDHSD17B10
SCHEMBL2117984 0.82 ALDH1A1 (0.69) KDM4EALDH1A1GAAHPGDHSD17B10
SCHEMBL6248036 0.82 PARP1 (0.50) KDM4EALDH1A1GAAHPGDHSD17B10
SCHEMBL30183620 0.82 ALDH1A1 (0.69) KDM4EALDH1A1GAAHPGDHSD17B10
SCHEMBL5320024 0.82 ALDH1A1 (0.58) KDM4EALDH1A1GAAHPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12630803-B2 Method of increasing proliferation of pancreatic beta cells, treatment method, and composition ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2026-05-19 US disclosed
US-20250136592-A1 C-LINKED INHIBITORS OF ENL/AF9 YEATS BRIDGE MEDICINES 2025-05-01 US disclosed
CN-115427035-B ENL/AF9 YEATS inhibitors 洛克菲勒大学 2025-04-22 CN disclosed
EP-4067347-B1 HETEROCYCLIC INHIBITORS OF CBP/EP300 FOR THE TREATMENT OF CANCER GENENTECH INC (US) 2024-06-19 EP disclosed
US-20240174983-A1 METHOD OF INCREASING PROLIFERATION OF PANCREATIC BETA CELLS, TREATMENT METHOD, AND COMPOSITION ICAHN SCHOOL MED MOUNT SINAI (US) 2024-05-30 US disclosed
CN-117858877-A C-linked inhibitors of ENL/AF9 YEATS 桥梁药品有限公司 2024-04-09 CN disclosed
EP-4337662-A1 C-LINKED INHIBITORS OF ENL/AF9 YEATS Bridge Medicines (US) 2024-03-20 EP disclosed
US-11897866-B2 Heteroaryl inhibitors of PAD4 PADLOCK THERAPEUTICS, INC. (US) 2024-02-13 US disclosed
US-11788064-B2 Method of increasing proliferation of pancreatic beta cells, treatment method, and composition ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2023-10-17 US disclosed
US-11788064-B2 Method of increasing proliferation of pancreatic beta cells, treatment method, and composition ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2023-10-17 US disclosed
WO-2017108282-A1 BICYCLIC HYDROXAMIC ACIDS USEFUL AS INHIBITORS OF MAMMALIAN HISTONE DEACETYLASE ACTIVITY KANCERA AB (SE) 2017-06-29 WO disclosed
US-20170015645-A1 SUBSTITUTED PYRAN DERIVATIVES UNIV WAYNE STATE (US) 2017-01-19 US disclosed
US-9458124-B2 Substituted pyran derivatives WAYNE STATE UNIVERSITY (US) 2016-10-04 US disclosed
US-20140309427-A1 Substituted Pyran Derivatives NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2014-10-16 US disclosed
US-8455476-B2 Azetidinyl diamides as monoacylglycerol lipase inhibitors JANSSEN PHARMACEUTICA, NV (BE) 2013-06-04 US disclosed
US-20100324014-A1 AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2010-12-23 US disclosed
US-20090270435-A1 Spiroketone Acetyl-CoA Carboxylase Inhibitors CORBETT JEFFREY WAYNE 2009-10-29 US disclosed
EP-2097420-A1 SPIROKETONE ACETYL-COA CARBOXYLASE INHIBITORS Pfizer Products Inc. (US) 2009-09-09 EP disclosed
WO-2008065508-A1 SPIROKETONE ACETYL-COA CARBOXYLASE INHIBITORS PFIZER PRODUCTS INC. (US) 2008-06-05 WO disclosed
WO-2007069053-A1 BENZIMIDAZOLE ANTAGONISTS OF THE H-3 RECEPTOR PFIZER PRODUCTS INC. (US) 2007-06-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170015645-A1 SUBSTITUTED PYRAN DERIVATIVES SLC18A2, SLC6A4, SLC6A3 KDM4E 3067/4885ALDH1A1 772/4885GAA 862/4885
US-11897866-B2 Heteroaryl inhibitors of PAD4 PADI4, PADI1, PADI6 KDM4E 117/4885ALDH1A1 956/4885GAA 904/4885
US-20240174983-A1 METHOD OF INCREASING PROLIFERATION OF PANCREATIC BETA CELLS, TREATMENT METHOD, AND COMPOSITION IAPP, DYRK1A, GLP1R KDM4E 2871/4885ALDH1A1 3491/4885GAA 1612/4885
US-12630803-B2 Method of increasing proliferation of pancreatic beta cells, treatment method, and composition GLP1R, DYRK1A, DYRK1B KDM4E 2363/4885ALDH1A1 4351/4885GAA 996/4885
US-11788064-B2 Method of increasing proliferation of pancreatic beta cells, treatment method, and composition IAPP, GLP1R, GPR119 KDM4E 2858/4885ALDH1A1 3769/4885GAA 1619/4885
US-20140309427-A1 Substituted Pyran Derivatives SLC18A2, SLC6A4, SLC6A3 KDM4E 3067/4885ALDH1A1 772/4885GAA 862/4885
US-20090270435-A1 Spiroketone Acetyl-CoA Carboxylase Inhibitors ACACA, PC, ACACB KDM4E 1062/4885ALDH1A1 212/4885GAA 1471/4885
US-20250136592-A1 C-LINKED INHIBITORS OF ENL/AF9 YEATS MLLT3, MLLT1, YEATS2 KDM4E 186/4885ALDH1A1 1756/4885GAA 2786/4885
US-20100324014-A1 AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS PNLIP, LPL, LIPA KDM4E 1931/4885ALDH1A1 364/4885GAA 22/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.